CERS · Healthcare · $480M
After-hours $2.37-0.42%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 114 Medical - Devices peers
Quarterly Revenue Growth
“이번 분기 가장 눈에 띄는 성과는 미국 내 IFC(혈액 응고 치료제) 사업이에요.”
In the company's words · 2026 1분기 earnings call